Nebula Research & Development LLC Blueprint Medicines Corp Call Options Transaction History
Nebula Research & Development LLC
- $836 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
350Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$646 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$642 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$521 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$383 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$267 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.77B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...